Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2025.

Sino American biotech BeiGene (Nasdaq: ONC; HKEX: 06160), a global oncology company that will change its name to BeOne ...

US President Donald Trump has signed an executive order attempting to restore a robust domestic manufacturing base for ...

A Seattle-based preclinical biotech comany developing novel neuroplastogens to treat neuropsychiatric and neurodegenerative ...

UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...

French drugmaker Ipsen (Euronext: IPN) today announced new data from two late-breaking presentations on Iqirvo (elafibranor) ...

Shares in Danish drugmaker Novo Nordisk were 3% higher on Wednesday afternoon after the company presented its first-quarter ...

NewLimit was founded to develop medicines that add healthy years to each human life. Initially, we thought it would take many ...

California-based Atara Biotherapeutics (Nasdaq: ATRA) revealed that the US Food and Drug Administration (FDA) has lifted the ...

The Russian government will consider registering next-in-class drugs based on data from the second phase of clinical trials ...

US biotech Aldeyra Therapeutics is making another attempt to gain marketing approval for its eye drop treatment reproxalap, a ...

The US Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign ...